PL1735349T3 - Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny - Google Patents

Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny

Info

Publication number
PL1735349T3
PL1735349T3 PL05735991T PL05735991T PL1735349T3 PL 1735349 T3 PL1735349 T3 PL 1735349T3 PL 05735991 T PL05735991 T PL 05735991T PL 05735991 T PL05735991 T PL 05735991T PL 1735349 T3 PL1735349 T3 PL 1735349T3
Authority
PL
Poland
Prior art keywords
assessing
risk
cardiovascular disease
ischemic cardiovascular
phosphorylcholine conjugates
Prior art date
Application number
PL05735991T
Other languages
English (en)
Inventor
Faire Ulf De
Johan Frostegaard
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of PL1735349T3 publication Critical patent/PL1735349T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
PL05735991T 2004-04-15 2005-04-15 Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny PL1735349T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52138404P 2004-04-15 2004-04-15
PCT/GB2005/001463 WO2005100405A2 (en) 2004-04-15 2005-04-15 Phosphorylcholine conjugates and corresponding antibodies
EP05735991A EP1735349B1 (en) 2004-04-15 2005-04-15 Method of assessing the risk of ischemic cardiovascular disease using phosphorylcholine conjugates

Publications (1)

Publication Number Publication Date
PL1735349T3 true PL1735349T3 (pl) 2011-03-31

Family

ID=34981497

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06077208T PL1797893T3 (pl) 2004-04-15 2005-04-15 Przeciwciała przeciwko koniugatom fosforylocholiny
PL05735991T PL1735349T3 (pl) 2004-04-15 2005-04-15 Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06077208T PL1797893T3 (pl) 2004-04-15 2005-04-15 Przeciwciała przeciwko koniugatom fosforylocholiny

Country Status (15)

Country Link
US (4) US8012483B2 (pl)
EP (3) EP1797893B1 (pl)
JP (2) JP4891228B2 (pl)
CN (4) CN1968965B (pl)
AT (2) ATE463254T1 (pl)
AU (2) AU2005233361B2 (pl)
CA (2) CA2776927C (pl)
CY (2) CY1110188T1 (pl)
DE (2) DE602005020474D1 (pl)
DK (2) DK1797893T3 (pl)
ES (2) ES2362222T3 (pl)
PL (2) PL1797893T3 (pl)
PT (2) PT1735349E (pl)
SI (2) SI1735349T1 (pl)
WO (1) WO2005100405A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101076254B (zh) 2004-12-22 2012-10-31 雅芳产品公司 减轻皱纹外观的方法和组合物
US20080160020A1 (en) * 2005-02-07 2008-07-03 Silverman Gregg J Methods For Reducing the Symptoms of Autoimmunity and Inflammation Using Binding Proteins Against Antigens Exposed on Dead or Dying Cells
US7745146B2 (en) * 2006-07-26 2010-06-29 Inova Diagnostics, Inc. Compositions and methods for diagnosing patients with acute atherosclerotic syndrome
WO2008080030A2 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Cardiovascular autoimmune disease panel and methods of using same
JP2011500868A (ja) * 2007-10-30 2011-01-06 アセラ・バイオテクノロジーズ・アーベー 心血管疾患用の診断及び治療法並びに組成物
AU2009267417A1 (en) * 2008-07-07 2010-01-14 Athera Biotechnologies Ab New therapeutic and diagnostic methods for Alzheimer's disease
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
EP2542580B1 (en) * 2010-03-04 2021-08-04 Athera Biotechnologies AB Antibodies against phosphorylcholine in combination therapy with biologic agents
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
US9310380B2 (en) 2010-11-17 2016-04-12 National University Corporation Ehime University Method for analyzing proteins contributing to autoimmune diseases, and method for testing for said diseases
EP2741770A4 (en) * 2011-08-09 2014-12-31 Athera Biotechnologies Ab ANTIBODIES FOR BINDING TO PHOSPHORYLCHOLINE (PC) AND / OR PC CONJUGATE
AR087485A1 (es) * 2011-08-09 2014-03-26 Athera Biotechnologies Ab Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
EP2953978B1 (en) 2013-02-05 2024-10-23 Tpcera Ltd. Phosphorylcholine conjugates and uses thereof
US10046021B2 (en) 2013-02-05 2018-08-14 Tpcera Ltd. Phosphorylcholine conjugates and uses thereof
US10500260B2 (en) * 2014-02-04 2019-12-10 3Dt Holdings, Llc Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
US11065319B2 (en) * 2014-02-04 2021-07-20 3Dt Holdings, Llc Methods for diagnosing and reducing incidences of cardiac allograft rejection
EP3208275B1 (en) 2014-10-15 2019-01-09 NOF Corporation Phosphorylcholine group-containing compound and phosphorylcholine complex
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
WO2018220224A1 (en) * 2017-06-02 2018-12-06 Medirista Biotechnologies Ab Lipid-related antigens and antibodies directed against them
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2024028192A1 (de) 2022-08-04 2024-02-08 Pentracor Gmbh Verwendung von phosphocholin-humanserumalbumin-konjugaten zur blockade von c-reaktivem protein

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
JPS6251699A (ja) * 1985-08-30 1987-03-06 Nichirei:Kk 単クロ−ン性抗体およびそれを用いる測定法
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE3751182T2 (de) 1986-08-06 1995-10-26 Scripps Clinic Res Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden.
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
AU5522390A (en) * 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) * 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
JP3183665B2 (ja) 1990-12-10 2001-07-09 エントルメド インコーポレーテッド コレステロール過剰血症およびアテローム性動脈硬化を防止するためのコレステロールに体するワクチン
WO1993018161A1 (en) * 1992-03-03 1993-09-16 The Rockefeller University Receptor complexes with b29 (ig-beta or ig-gamma) and their uses
AU5959494A (en) 1992-12-29 1994-07-19 Entremed, Inc Vaccines against sterols
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
US5455032A (en) * 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
AU1159497A (en) 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
ES2205853T3 (es) 1998-07-03 2004-05-01 Athera Biotechnologies Ab Metodo para diagnosticar la enfermedad cardiovascular y la aterosclerosis precoz.
ATE506615T1 (de) * 1999-10-26 2011-05-15 Univ California Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
WO2001088547A2 (en) 2000-05-12 2001-11-22 The Regents Of The University Of California Standardized oxidized ldl assay
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2004091520A2 (en) 2003-04-11 2004-10-28 The Regents Of The University Of California Methods and compositions for treating atherosclerosis

Also Published As

Publication number Publication date
PT1735349E (pt) 2010-12-14
CN1968965B (zh) 2015-12-16
EP2258728A1 (en) 2010-12-08
CY1111659T1 (el) 2015-10-07
US20160131661A1 (en) 2016-05-12
JP5366987B2 (ja) 2013-12-11
SI1797893T1 (sl) 2010-08-31
JP4891228B2 (ja) 2012-03-07
ES2362222T3 (es) 2011-06-29
DK1797893T3 (da) 2010-08-02
EP1797893B1 (en) 2010-04-07
AU2011202334B2 (en) 2012-12-06
AU2005233361A1 (en) 2005-10-27
CN103908669A (zh) 2014-07-09
EP1735349B1 (en) 2010-09-08
EP1797893A2 (en) 2007-06-20
CY1110188T1 (el) 2015-01-14
US8012483B2 (en) 2011-09-06
AU2005233361B2 (en) 2011-02-24
WO2005100405A2 (en) 2005-10-27
WO2005100405A3 (en) 2006-04-13
PL1797893T3 (pl) 2010-09-30
CN103743898A (zh) 2014-04-23
CN103908669B (zh) 2017-07-04
US20120039895A1 (en) 2012-02-16
EP1797893A3 (en) 2007-06-27
CA2776927C (en) 2014-08-12
DE602005020474D1 (de) 2010-05-20
CA2776927A1 (en) 2005-10-27
CA2562550C (en) 2013-09-24
CN103743898B (zh) 2019-02-05
US10222382B2 (en) 2019-03-05
US20070286868A1 (en) 2007-12-13
JP2008501636A (ja) 2008-01-24
ATE463254T1 (de) 2010-04-15
SI1735349T1 (sl) 2010-12-31
DE602005023428D1 (de) 2010-10-21
CN105699669A (zh) 2016-06-22
ATE480778T1 (de) 2010-09-15
EP1735349A2 (en) 2006-12-27
DK1735349T3 (da) 2010-12-06
CA2562550A1 (en) 2005-10-27
US20140186360A1 (en) 2014-07-03
AU2011202334A1 (en) 2011-06-09
JP2011099871A (ja) 2011-05-19
PT1797893E (pt) 2010-07-14
ES2357606T3 (es) 2011-04-28
CN1968965A (zh) 2007-05-23

Similar Documents

Publication Publication Date Title
SI1735349T1 (sl) Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov
HK1216080A1 (zh) 用於治療或預防草酸鹽相關疾病的組合物和方法
NO20054451D0 (no) Fremgangsmate og innretning for friksjonssveising
DK1955102T3 (da) Fremgangsmåde og indretning til konfokal billedbehandling
NO20053843D0 (no) Fremgangsmate og anordning for friksjonssveising.
DE602006019404D1 (de) Docetaxel-immuntest
ITMI20061751A1 (it) Albero cavo e procedimento per la realizzazione
WO2008060618A3 (en) Use of genetic determinants in cardiovascular risk assessment
EP1774029A4 (en) METHOD FOR DETECTING THE RISKS OF NON-INSULIN-DEPENDENT DIABETES AND FOR TREATING THIS TYPE OF DIABETES
EP1978034A4 (en) ANTI-PERIOSTINE ANTIBODIES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PERIOSTIN-RELATED DISEASE CONTAINING THE ANTIBODY
WO2006138048A3 (en) Formulations comprising fluphenazine or derivatives thereof
FI20045295A0 (fi) Embossauslaite ja menetelmä embossauslaitteen säätämiseksi
MX2007009591A (es) Metodos para disposicion mejorada de farmacos.
EP1930689A4 (en) LASER SPACING MEASURING DEVICE AND LASER SPACING MEASURING METHOD
FI20011370A0 (fi) Biotunnistusmenetelmä ja sitä hyödyntävä laite
NL1021785A1 (nl) Inrichting en werkwijze voor het belichten van een object.
WO2006074443A3 (en) Pde5 inhibitor compositions and methods for immunotherapy
ITTO20030365A1 (it) Dispositivo e procedimento per determinare la posizione
ATE377608T1 (de) Hemoglobin konjugate
ITCR20040011A1 (it) Struttura metallica per pedane, rampe e simili, adatta a compensare o superare dislivelli
ITUD20040001A1 (it) Procedimento per la rilevazione in linea
NL1031169A1 (nl) Werkwijze voor de vervaardiging van een railbovendeel alsmede railbovendeel.
ITFI20050159A1 (it) Metodo di imaging ecografico per la caratterizzazione delle proprieta' non lineari di un mezzo e dispositivo impiegante detto metodo
ITMO20050169A1 (it) ''pannello per mobili o simili''.
ITRM20040483A1 (it) Depolveratore per polveri di pietra arenaria o simili.